Mumbai, Sept. 2 -- The product is the therapeutic equivalent of Halaven Injection (1 mg/2 mL), originally developed by Eisai, Inc. Glenmark's version has been deemed bioequivalent and therapeutically equivalent by the U.S. Food and Drug Administration (USFDA), paving the way for its entry into the oncology segment of the U.S. injectable market.

According to IQVIA sales data for the 12-month period ending July 2025, Halaven Injection recorded annual sales of approximately $66.3 million in the United States.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, "We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. As the first complex generic in our...